GFH276

DRUG3 trials

Sponsors

Genfleet Therapeutics (Shanghai) Inc.

Conditions

Advanced Solid Tumors CancerCRC (Colorectal Cancer)CancerNSCLCPDACPancreatic CancerPancreatic Ductal AdenocarcinomaRAS Mutation

Phase 1

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Not yet recruitingNCT07198321

Genfleet Therapeutics (Shanghai) Inc.Cancer, CRC (Colorectal Cancer), NSCLC +1

Start: 2025-09-22End: 2027-12-30Target: 450Updated: 2025-09-30

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Not yet recruitingNCT07678593

Genfleet Therapeutics (Shanghai) Inc.Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation

Start: 2026-09-01End: 2028-09-01Target: 222Updated: 2026-07-10

Phase 2

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Not yet recruitingNCT07784374

Genfleet Therapeutics (Shanghai) Inc.Pancreatic Cancer

Start: 2026-08-31End: 2029-08-31Target: 120Updated: 2026-08-25

Related Papers

Abstract 4565: Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors

Cancer Research2026-04-03